Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Paramatta, Australia Clinical Trials

A listing of Paramatta, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (72) clinical trials

A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

The study will assess the rate of change of the area of GA secondary to AMD by measuring FAF in up to 330 participants with GA due to AMD being treated with IONIS-FB-LRx. The study is a Phase 2, double-masked, randomized, stratified, placebo-controlled study conducted at multiple centers. It is ...

Phase

0.0 miles

Learn More »

Phase II Sequential Treatment Trial of Single Agent Nivolumab Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)

This study aims to evaluate the safety, tolerability and effectiveness of new treatments for kidney cancer called Nivolumab and Ipilimumab. The study is in two parts; in the first instance patients receive nivolumab alone. If this treatment is not effective patients may move onto the second part of the trial, ...

Phase

1.19 miles

Learn More »

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the "spot sign", have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.

Phase

1.19 miles

Learn More »

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Primary Objectives: To estimate the progression free survival distribution of WNT-medulloblastoma patients treated on Stratum W1 with reduced-dose craniospinal irradiation and reduced-dose cyclophosphamide. To estimate progression-free survival distribution of Non-WNT Non-SHH medulloblastoma patients treated on Stratum N1 with reduced dose cyclophosphamide. To evaluate the effect of an aerobic training intervention, ...

Phase

1.19 miles

Learn More »

A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer

The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.

Phase

1.19 miles

Learn More »

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.

Phase

1.19 miles

Learn More »

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Phase

1.19 miles

Learn More »

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib Docetaxel or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

Phase

1.19 miles

Learn More »

Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT

This is a phase 2, multicenter, open-label, single arm estimation study in adult subjects with high-risk DLBCL in complete remission. The study will consist of up to a 28-day screening period, a run-in period of up to 24 months, a 12-week treatment period (8 weeks of blinatumomab treatment followed by ...

Phase

1.19 miles

Learn More »

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment

The study will be comprised of a screening period, a treatment period (up to 2 years) and a long term follow-up. Eligible patients will be treated with intratumoral tavo-EP to the accessible lesions on Days 1, 5 and 8 every 6 weeks and with IV pembrolizumab (200mg) on Day 1 ...

Phase

1.19 miles

Learn More »